- Home
- IDR vs FDMT Comparison
IDR vs FDMT Comparison
Compare IDR & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IDR | FDMT |
|---|---|---|
| Founded | 1996 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 579.4M | 476.9M |
| IPO Year | 2000 | 2019 |
Fundamental Metrics
Financial Performance| Metric | IDR | FDMT |
|---|---|---|
| Price | $38.89 | $8.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $17.50 | ★ $34.13 |
| AVG Volume (30 Days) | 417.4K | ★ 707.9K |
| Earning Date | 01-01-0001 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 644.44 | N/A |
| EPS | ★ 0.51 | N/A |
| Revenue | ★ $25,765,373.00 | $37,000.00 |
| Revenue This Year | $55.62 | $21,227.03 |
| Revenue Next Year | $23.93 | $161.87 |
| P/E Ratio | $75.31 | ★ N/A |
| Revenue Growth | ★ 88.66 | N/A |
| 52 Week Low | $10.45 | $2.24 |
| 52 Week High | $54.70 | $12.34 |
Technical Indicators
Market Signals| Indicator | IDR | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 48.18 | 52.62 |
| Support Level | $37.01 | $8.95 |
| Resistance Level | $40.25 | $9.78 |
| Average True Range (ATR) | 2.92 | 0.56 |
| MACD | 0.14 | 0.02 |
| Stochastic Oscillator | 66.95 | 48.03 |
Price Performance
Historical ComparisonAbout IDR Idaho Strategic Resources Inc.
Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. It produces gold at the Golden Chest Mine. In addition to gold and gold production, the company maintains a strategic and domestic presence in the Critical Minerals sector and is focused on advancing its officially recognized Lemhi Pass, Diamond Creek, and Roberts Rare Earth Element projects in central Idaho.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.